A. Tufman (München, Germany), R. Huber (Munich, Germany)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Impact of the COVID19 pandemic on patterns of respiratory, thoracic oncology and thoracic surgery outpatient care
G. Hardavella (Athens, Greece), E. Babaliari (Athens, Greece), E. Bellou (Athens, Greece), I. Karampinis (Athens, Greece), E. Keramida (Athens, Greece), P. Demertzis (Athens, Greece)
|   |
Delayed interval scanning is not associated with stage-shift at diagnosis: Preliminary results to support guidelines for lung cancer screening during the COVID-19 pandemic
A. Creamer (London, United Kingdom), J. Dickson (London, United Kingdom), C. Horst (London, United Kingdom), S. Tisi (London, United Kingdom), H. Hall (London, United Kingdom), P. Verghese (London, United Kingdom), J. Mccabe (London, United Kingdom), K. Gyertson (London, United Kingdom), A. Mullin (London, United Kingdom), L. Farrelly (London, United Kingdom), C. Clark (Menlo Park, United States of America), S. Hamilton (Menlo Park, United States of America), B. Allen (Menlo Park, United States of America), A. Hackshaw (London, United Kingdom), A. Devaraj (London, United Kingdom), A. Nair (London, United Kingdom), S. Janes (London, United Kingdom)
| |
Collateral impact of COVID19 pandemic on lung cancer services in a tertiary referral centre
G. Hardavella (Athens, Greece), E. Babaliari (Athens, Greece), E. Bellou (Athens, Greece), I. Karampinis (Athens, Greece), E. Keramida (Athens, Greece), I. Bracka (Athens, Greece), P. Demertzis (Athens, Greece)
| |
Lung nodule management in Covid-19;does postponed surveillance matter?
R. Ratnakumar (London, United Kingdom), J. Fraser (London, United Kingdom), R. Nicholls (London, United Kingdom), J. Quint (London, United Kingdom), S. Bloch (London, United Kingdom)
| |
The Covid-19 pandemic and lung cancer: psychological and diagnosis impacts
M. Hamoudi (Sfax, Tunisia), R. Khemakhem (Sfax, Tunisia), M. Sidi Oumare (Sfax, Tunisia), N. Kallel (Sfax, Tunisia), R. Gargouri (Sfax, Tunisia), I. Yangui (Sfax, Tunisia), H. Ayadi (Sfax, Tunisia), W. Feki (Sfax, Tunisia), S. Kammoun (Sfax, Tunisia)
| |
Increase in lung cancer emergency presentations during the COVID-19 pandemic
C. Vella (Msida, Malta), A. Ashraf (Leicester, United Kingdom), R. Sudhir (Leicester, United Kingdom), P. Pinglay (Leicester, United Kingdom), I. Das (Leicester, United Kingdom), M. Chowdhry (Leicester, United Kingdom), A. Nakas (Leicester, United Kingdom), C. Richards (Leicester, United Kingdom), S. Thiagarajan (Leicester, United Kingdom), R. Panchal (Leicester, United Kingdom), S. Ahmed (Leicester, United Kingdom), S. Agrawal (Leicester, United Kingdom), M. Tufail (Leicester, United Kingdom), J. Bennett (Leicester, United Kingdom)
| |
Effect of quarantine ?n hospital admissions for lung cancer
I. Sigala (Athens, Greece), V. Giannakoulis (Athens, Greece), T. Giannakas (Athens, Greece), E. Zervas (Athens, Greece), A. Brinia (Athens, Greece), N. Gianniou (Athens, Greece), E. Dima (Athens, Greece), A. Asimakos (Athens, Greece), P. Katsaounou (Athens, Greece)
| |
Thoracic cancer patients and Covid-19: experience from a portuguese tertiary care unit
R. Viana (Leiria, Portugal), D. Coutinho (Vila Nova de Gaia, Portugal), E. Silva (Vila Nova de Gaia, Portugal), S. Campainha (Vila Nova de Gaia, Portugal), M. Dias (Vila Nova de Gaia, Portugal), T. Costa (Vila Nova de Gaia, Portugal), A. Barroso (Vila Nova de Gaia, Portugal)
| |
Lung Cancer vs. „Young Cancer“ – Is There a Difference?
M. Bratová (Brno, Czech Republic), K. Hurdalkova (Brno, Czech Republic), M. Drosslerova (Praque, Czech Republic), J. Kultan (Olomouc, Czech Republic), M. Wanke (Hradec Kralove, Czech Republic), M. Svaton (Pilsen, Czech Republic), K. Brat (Brno, Czech Republic)
| |
Non-small cell lung cancer: how do experts want to be treated?
N. Aksel (Izmir, Turkey), B. Aktin Yoldas (Izmir, Turkey), E. Kirakli (Izmir, Turkey), I. Petekkaya (Izmir, Turkey)
| |
Evolution in the diagnostic approach to lung cancer
J. Da Silva Arana Fonseca Ribeiro (Guarda, Portugal), G. Samouco (Guarda, Portugal), R. Martins Natal (Guarda, Portugal), S. Braga (Guarda, Portugal), F. Luís (Guarda, Portugal), L. Ferreira (Guarda, Portugal), R. Matos Gomes (Guarda, Portugal), L. Vaz Rodrigues (Guarda, Portugal)
| |
Evaluation of cancer-associated thrombosis risk in patients with lung adenocarcinoma using the COMPASS-CAT risk assessment model
M. Chrysanthidis (Athens, Greece), A. Charpidou (Athens, Greece), E. Dimakakos (Athens, Greece), D. Grapsa (Athens, Greece), P. Bakakos (Athens, Greece), G. Stratakos (Athens, Greece), K. Syrigos (Athens, Greece)
| |
Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer
Y. Kagawa (Aichi, Japan), T. Uemura (Aichi, Japan), M. Horiuchi (Aichi, Japan), S. Fukuda (Aichi, Japan), K. Maeno (Aichi, Japan), T. Oguri (Aichi, Japan), N. Takeda (Aichi, Japan), K. Fukumitsu (Aichi, Japan), T. Tajiri (Aichi, Japan), H. Ohkubo (Aichi, Japan), Y. Ito (Aichi, Japan), A. Niimi (Aichi, Japan)
| |
End-of-life antimicrobial usage in lung cancer: current perpectives and clinical practice
A. Santos Camelo Pimenta (Vila Real, Portugal), I. Rodrigues (Vila Real, Portugal), L. Nascimento (Vila Real, Portugal), S. Raimundo (Vila Real, Portugal), T. Gomes (Vila Real, Portugal), A. Fernandes (Vila Real, Portugal)
| |
The causes and consequences for dose reduction in NSCLC IIIB patients, a retrospective single center clinical trial.
W. Parsch (Nuremberg, Germany), L. Thiesing (Nuremberg, Germany), D. Würflein (Nuremberg, Germany), J. Ficker (Nuremberg, Germany), W. Brückl (Nuremberg, Germany)
| |
Absolute neutrophil count in peripheral blood predict prognosis in lung cancer patients treated with anlotinib
R. Chen (Shanghai, China), . Lu (Shanghai, China), M. Zhou (Shanghai, China), Y. Guo (Shanghai, China)
| |
Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: Three case studies.
C. Bickert (Munich, Germany), K. Kahnert (Munich, Germany), D. Kauffmann-Guerrero (Munich, Germany), J. Götschke (Munich, Germany), Z. Syunyaeva (Munich, Germany), J. Behr (Munich, Germany), A. Tufman (Munich, Germany)
| |
Surgery for Lung cancer in patients under 45 years old: what are particularities?
m. Abdennadher (Ariana, Tunisia), M. Hadj Dahmane (Ariana, Tunisia), H. Zribi (Ariana, Tunisia), S. Zairi (Ariana, Tunisia), I. Bouacida (Ariana, Tunisia), H. Neji (Ariana, Tunisia), S. Ouerghi (Ariana, Tunisia), M. Mlika (Ariana, Tunisia), A. Marghli (Ariana, Tunisia)
| |
Surgical and survival outcomes of sleeve lobectomy after neoadjuvant theraphy in lung cancer: With group of 265 patients
K. Ceylan (IZMIR, Turkey), A. Ucvet (IZMIR, Turkey), B. Arabaci (IZMIR, Turkey), S. Yazgan (IZMIR, Turkey), S. Gursoy (IZMIR, Turkey)
| |